Drugs & Aging

, Volume 22, Issue 10, pp 859–876 | Cite as

Prevention of Cardiovascular Events in Elderly People

  • Wafik Farah Andrawes
  • Caroline Bussy
  • Joël Belmin
Original Research Article


Background and objective

Cardiovascular disease has been identified as the leading cause of morbidity and mortality in developed countries. Given the increase in life expectancy and the development of cardiovascular preventive measures, it has become increasingly important to detect and prevent cardiovascular diseases in the elderly. We reviewed the scientific literature concerning cardiovascular prevention to assess the importance of cardiovascular preventive measures in old (≥65 years of age) individuals.


We undertook a systematic search for references relating to prevention of cardiovascular disease in the elderly, mainly ischaemic stroke, coronary artery disease and heart failure, on the MEDLINE database 1962–2005. For cardiovascular prevention by drugs or surgery, emphasis was placed on randomised controlled trials, review articles and meta-analyses. For cardiovascular prevention by lifestyle modification, major cohort studies were also considered.


Stroke, coronary heart disease and heart failure were found to be the main targets for cardiovascular prevention in published studies. Antihypertensive treatment has proven its efficacy in primary prevention of fatal or nonfatal stroke in hypertensive and high-risk patients >60 years of age, particularly through treatment of systolic hypertension. Systolic blood pressure reduction is equally important in the secondary prevention of stroke. Similarly, in nonvalvular atrial fibrillation, an adjusted dose of warfarin with a target International Normalized Ratio (INR) of between 2 to 3 prevents ischaemic stroke in elderly patients with an acceptable haemorrhagic risk but is still under prescribed. Antiplatelet agents are indicated in elderly patients with nonembolic strokes. Few large-scale studies have investigated the effect of HMG-CoA reductase inhibitors (statins) on stroke prevention in old individuals. To date, the largest trials suggest a beneficial effect for stroke prevention with use of statins in high-risk elderly subjects ≤82 years of age. Carotid endarterectomy is indicated in carotid artery stenosis >70% and outcomes are even better in elderly than in younger patients. However, medical treatment is still the first-line treatment in asymptomatic elderly patients with <70% stenosis. In ischaemic heart disease, different trials in elderly individuals have shown that use of statins, antithrombotic agents, β-adrenoceptor antagonists and ACE inhibitors plays an important role either in primary or in secondary cardiovascular prevention. Hormone replacement therapy has been used to treat climacteric symptoms and postmenopausal osteoporosis and was thought to confer a cardiovascular protection. However, controlled trials in elderly individuals changed this false belief when it was found that there was no benefit and even a harmful cardiovascular effect during the first year of treatment. Smoking cessation, regular physical activity and healthy diet are, as in younger individuals, appropriate and effective measures for preventing cardiovascular events in the elderly. Finally, antihypertensive treatment and influenza vaccination are useful for heart failure prevention in elderly individuals.


Cardiovascular prevention should be more widely implemented in the elderly, including individuals aged ≥75 years, and this might contribute to improved healthy status and quality of life in this growing population.


Atrial Fibrillation Warfarin Hormone Replacement Therapy International Normalize Ratio Elderly Subject 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



No sources of funding were used to assist in the preparation of this study. The authors have no conflicts of interest that are directly relevant to the content of this study.


  1. 1.
    Stary HC. Evolution and progression of atherosclerosis in coronary arteries of children and young adults. Arteriosclerosis 1989; 9Suppl. 1: 119–32Google Scholar
  2. 2.
    National Cholesterol Education Program. Report of the Expert Panel on Population Strategies for Blood Cholesterol Reduction. Arch Intern Med 1991; 151: 1071–84CrossRefGoogle Scholar
  3. 3.
    National Cholesterol Education Program. Second report of the Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Circulation 1994; 89: 1333–445CrossRefGoogle Scholar
  4. 4.
    Castelli WB, Garrison RJ, Wilson PNF, et al. The incidence of coronary artery disease and lipoprotein cholesterol levels: the Framingham study. JAMA 1986; 256: 2835–8PubMedCrossRefGoogle Scholar
  5. 5.
    Multiple Risk Factor Intervention Trial Research Group. Multiple Risk Factor Intervention Trial risk factor changes and mortality results. JAMA 1982; 248: 1465–76CrossRefGoogle Scholar
  6. 6.
    Assmann G, Schulte H. The Prospective Cardiovascular Muenster (PROCAM) Study: prevalence of hypertension and/or diabetes mellitus and the relation to coronary heart disease. Am Heart J 1988; 116: 1713–24PubMedCrossRefGoogle Scholar
  7. 7.
    Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999; 340: 115–26PubMedCrossRefGoogle Scholar
  8. 8.
    Fuster V. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation 1994; 90: 2126–46PubMedCrossRefGoogle Scholar
  9. 9.
    Schwartz CJ, Mitchell JRA. Cellular infiltration of the human arterial adventitia associated with atheromatous plaques. Circulation 1962; 26: 73–8PubMedCrossRefGoogle Scholar
  10. 10.
    Kaartinen M, Penttila A, Kovanen PT. Accumulation of activated mast cells in the shoulder region of human coronary atheroma, the predilection site of atheromatous rupture. Circulation 1994; 90: 1669–78PubMedCrossRefGoogle Scholar
  11. 11.
    World Health Organization. World health report 1999. Geneva: WHO, 1999Google Scholar
  12. 12.
    Bonita R. Epidemiology of stroke. Lancet 1992; 339: 342–4PubMedCrossRefGoogle Scholar
  13. 13.
    Warlow CP, Dennis MS, van Gijn G, et al. What caused this transient persisting ischaemic event? In: Warlow CP, Dennis HS, van Gijn J, et al., editors. Stroke: a practical guide to management. Oxford: Blackwell Science, 2001: 223–300Google Scholar
  14. 14.
    Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effect of treatment on morbidity in hypertension: III. Influence of age, diastolic pressure and prior cardiovascular disease: future analysis of side effects. Circulation 1972; 45: 991–1004CrossRefGoogle Scholar
  15. 15.
    Hypertension Detection and Follow-up Program Cooperative Group. Five year findings of the Hypertension Detection and Follow-Up Program: II. Mortality by race, sex and age. JAMA 1979; 242: 2572–7CrossRefGoogle Scholar
  16. 16.
    Management Committee of the National Heart Foundation of Australia. Treatment of mild hypertension in the elderly. Med J Aust 1981; 2: 398–402Google Scholar
  17. 17.
    The Dutch TIA Trial Study Group. Trial of secondary prevention with atenolol after transient ischemic attack or non disabling ischemic stroke. Stroke 1993; 24: 543–8CrossRefGoogle Scholar
  18. 18.
    Coope J, Warrender TS. Randomised trial of treatment of hypertension in elderly patients in primary care. BMJ 1986; 293: 1145–51PubMedCrossRefGoogle Scholar
  19. 19.
    MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992; 304: 405–12CrossRefGoogle Scholar
  20. 20.
    Eriksson S, Olofsson BO, Wester PO, for the TEST study group. Atenolol in secondary prevention after stroke. Cerebrovasc Dis 1995; 5: 21–5CrossRefGoogle Scholar
  21. 21.
    Amery A, Birkenhager W, Brixko P, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet 1985; I: 1349–54CrossRefGoogle Scholar
  22. 22.
    SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255–64CrossRefGoogle Scholar
  23. 23.
    Dahlof B, Lindholm LH, Hansson L, et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991; 338: 1281–5PubMedCrossRefGoogle Scholar
  24. 24.
    Bulpitt CJ, Beckett NS, Cooke J, et al. Hypertension in the Very Elderly Trial Working Group: results of the pilot study for the Hypertension in the Very Elderly Trial. J Hypertens 2003; 21: 2409–17PubMedCrossRefGoogle Scholar
  25. 25.
    MacMahon S, Sharpe N, Gamble G, et al. Randomized placebo controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or occlusive arterial disease: prevention of atherosclerosis with ramipril. J Am Coll Cardiol 2000; 36: 438–43PubMedCrossRefGoogle Scholar
  26. 26.
    Teo KK, Burton JR, Buller CE, et al. Long term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: the Simvastatin/enalapril Coronary Atherosclerosis Trial (SCAT). Circulation 2000; 102: 1748–54PubMedCrossRefGoogle Scholar
  27. 27.
    PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischemic attack. Lancet 2001; 358: 1033–41CrossRefGoogle Scholar
  28. 28.
    Heart Outcomes Prevention Evaluation Study Investigators (HOPE). Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145–53CrossRefGoogle Scholar
  29. 29.
    Thijs L, Staessen JA, Beleva S, et al. How well can blood pressure be controlled? Progress report on the Systolic Hypertension in Europe: follow-up study (Syst-Eur2). Curr Control Trials Cardiovasc Med 2001; 2: 298–306PubMedCrossRefGoogle Scholar
  30. 30.
    MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke and coronary heart disease: prolonged difference in blood pressure: prospective observational study corrected for the regression dilution bias. Lancet 1990; 335: 765–74PubMedCrossRefGoogle Scholar
  31. 31.
    Mulrow CD, Cornell JA, Herrera CR, et al. Hypertension in the elderly: implication and generalizability of randomized trials. JAMA 1994; 272: 1932–8PubMedCrossRefGoogle Scholar
  32. 32.
    Staessen JA, Gazowski J, Wang JG, et al. Risk of untreated and treated isolated systolic hypertension in the elderly: meta analysis of outcome trials. Lancet 2000; 355: 865–72PubMedCrossRefGoogle Scholar
  33. 33.
    Lawes CM, Bennett DA, Feigin VL, et al. Blood pressure and stroke: an overview of published reviews. Stroke 2004; 35: 1024–33PubMedCrossRefGoogle Scholar
  34. 34.
    Gueyffier F, Bulpitt C, Boissel JP, et al. Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. Lancet 1999; 353: 793–6PubMedCrossRefGoogle Scholar
  35. 35.
    Bosch J, Yusuf S, Pogue J, et al. Heart Outcomes Prevention Evaluation: use of ramipril in preventing stroke: double blind randomised trial. BMJ 2002; 324: 699–702PubMedCrossRefGoogle Scholar
  36. 36.
    Kannel WB, Abbot RD, Savage DD, et al. Epidemiological features of atrial fibrillation: the Framingham study. N Engl J Med 1982; 306: 1018–22PubMedCrossRefGoogle Scholar
  37. 37.
    Wolf PA, Dawber TR, Thomas Jr HE, et al. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology 1978; 28: 973–7PubMedCrossRefGoogle Scholar
  38. 38.
    Lip GY, Lowe GD. Antithrombotic treatment for atrial fibrillation. BMJ 1996; 312: 45–9PubMedCrossRefGoogle Scholar
  39. 39.
    Atrial Fibrillation Investigators. Risk factor for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomised controlled trials. Arch Intern Med 1994; 154: 1449–57CrossRefGoogle Scholar
  40. 40.
    Hart R, Benavente O, McBride R, et al. Antithrombotic therapy to prevent stroke in patient with atrial fibrillation: a meta-analysis. Ann Intern Med 1999; 131: 492–501PubMedGoogle Scholar
  41. 41.
    Connolly SJ. The Atrial Fibrillation Investigators: stroke prevention in atrial fibrillation II study. Lancet 1994; 343: 1508–9CrossRefGoogle Scholar
  42. 42.
    Stroke Prevention in Atrial Fibrillation Investigators. Adjusted dose warfarin versus low intensity, fixed dose warfarin plus aspirin for high risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996; 348: 633–8CrossRefGoogle Scholar
  43. 43.
    The European Atrial Fibrillation Trial Study Group. Optimal oral anticoagulant therapy in patients with non rheumatic atrial fibrillation and recent cerebral ischemia: the European Atrial Fibrillation Trial Study Group. N Engl J Med 1995; 333: 5–10CrossRefGoogle Scholar
  44. 44.
    Levine MN, Chair MS, Raskob G, et al. Hemorrhagic complications of anticoagulant treatment. Chest 2001; 119: 108S–21SPubMedCrossRefGoogle Scholar
  45. 45.
    Van der Meer FJ, Rosendall FR, Vanderbroocke JP, et al. Bleeding complications in oral anticoagulant therapy, an analysis of risk factors. Arch Intern Med 1993; 153: 1557–62PubMedCrossRefGoogle Scholar
  46. 46.
    Palareti G, Hirsh J, Legnani C, et al. Oral anticoagulant treatment in elderly: a nested prospective, case control study. Arch Intern Med 2000; 160: 470–8PubMedCrossRefGoogle Scholar
  47. 47.
    Fihn SD, Callahan CM, Martin DC, et al. The risk for and severity of bleeding complications in elderly patients treated with warfarin: the National Consortium of Anticoagulation Clinics. Ann Intern Med 1996; 124: 970–9PubMedGoogle Scholar
  48. 48.
    Brass LM, Krumholz HM, Scinto JM, et al. Warfarin use among patients with atrial fibrillation. Stroke 1997; 28: 2382–9PubMedCrossRefGoogle Scholar
  49. 49.
    White RH, McBurnie MA, Manolio T, et al. Oral anticoagulation in patients with atrial fibrillation: adherence with guidelines in an elderly cohort. Am J Med 1999; 106: 165–71PubMedCrossRefGoogle Scholar
  50. 50.
    Go AS, Hylek EM, Chang Y, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA 2003; 290: 2685–92PubMedCrossRefGoogle Scholar
  51. 51.
    Vasishta S, Toor F, Johansen A, et al. Stroke prevention in atrial fibrillation: physicians’ attitudes to anticoagulation in older people. Arch Gerontol Geriatr 2001; 33: 219–26PubMedCrossRefGoogle Scholar
  52. 52.
    Man-Son-Hing M, Nichol G, Lau A, et al. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk of falls. Arch Intern Med 1999; 159: 677–85PubMedCrossRefGoogle Scholar
  53. 53.
    Albers GW, Diener HC, Frison L, et al. Ximelagatran vs warfarin for stroke prevention in patients with non valvular atrial fibrillation: a randomized trial. JAMA 2005; 293: 690–8PubMedCrossRefGoogle Scholar
  54. 54.
    Zhang X, Patel A, Horibe H, et al. Cholesterol, coronary heart disease, and stroke in the Asia Pacific region. Int J Epidemiol 2003; 32: 563–72PubMedCrossRefGoogle Scholar
  55. 55.
    Rodriguez BL, D’Agostino R, Abbott RD, et al. Risk of hospitalized stroke in men enrolled in the Honolulu Heart Program and the Framingham Study: a comparison of incidence and risk factor effects. Stroke 2002; 33: 230–6PubMedCrossRefGoogle Scholar
  56. 56.
    Scandinavian Simvastatin Survival study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–9Google Scholar
  57. 57.
    Plehn JF, Davis BR, Sacks FM, et al., for the CARE Investigators. Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) Study. Circulation 1999; 99: 216–23PubMedCrossRefGoogle Scholar
  58. 58.
    West Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998; 97: 1440–5CrossRefGoogle Scholar
  59. 59.
    Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360: 1623–30PubMedCrossRefGoogle Scholar
  60. 60.
    Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high risk conditions. Lancet 2004; 363: 757–67CrossRefGoogle Scholar
  61. 61.
    Pohjasvaara T, Erkinjuntii T, Vataja R, et al. Comparison of stroke features and disability in daily life in patients with ischemic stroke aged 55 to 70 and 71 to 85 years. Stroke 1997; 28: 729–35PubMedCrossRefGoogle Scholar
  62. 62.
    European Carotid Surgery Trialists’ Collaborative group. MRC European Carotid Surgery Trial: interim result for symptomatic patients with severe (70–99) or mild (0–29) carotid stenosis. Lancet 1991; 337: 1235–43CrossRefGoogle Scholar
  63. 63.
    Alamowitch S, Eliasziw M, Algra A, et al. Risk, causes, and prevention of ischemic stroke in elderly patients with symptomatic internal carotid artery stenosis. Lancet 2001; 357: 1154–60PubMedCrossRefGoogle Scholar
  64. 64.
    Barnett H. The appropriate use of carotid endarterectomy. CMAJ 2002; 166: 1169–79PubMedGoogle Scholar
  65. 65.
    Asymptomatic Carotid Atherosclerosis Study Group. Study design for randomised prospective trial of carotid endarterectomy for asymptomatic atherosclerosis. Stroke 1989; 20: 844–9CrossRefGoogle Scholar
  66. 66.
    Swedish Aspirin Low-Dose Trial (SALT) of 75mg aspirin as secondary prophylaxis after cerebrovascular ischemic events. The SALT Collaborative Group. Lancet 1991; 338: 1345–9Google Scholar
  67. 67.
    Gent M, Blakely JA, Easton JD, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989; I: 1215–20CrossRefGoogle Scholar
  68. 68.
    Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143: 1–13PubMedCrossRefGoogle Scholar
  69. 69.
    Gorelick PB, Richardson D, Kelly M, et al. Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial. JAMA 2003; 289: 2947–57PubMedCrossRefGoogle Scholar
  70. 70.
    CAPRIE Steering Committee. A randomized, blinded trial of Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE). Lancet 1996; 348: 1329–39CrossRefGoogle Scholar
  71. 71.
    Antithrombotic Trialists’ Collaboration. Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71–86CrossRefGoogle Scholar
  72. 72.
    Antiplatelet Trialists Collaboration. Collaborative overview of randomized trials of antiplatelet therapy: I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81–106CrossRefGoogle Scholar
  73. 73.
    Griffin G. Antiplatelet therapy and anticoagulation in patients with hypertension. Am Fam Physician 2005; 71: 897–9PubMedGoogle Scholar
  74. 74.
    Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755–62PubMedCrossRefGoogle Scholar
  75. 75.
    Mohr JP, Thompson JLP, Lazar RM, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001; 345: 1444–51PubMedCrossRefGoogle Scholar
  76. 76.
    Algra A, De Schryver ELLM, van Gijn J, et al. Oral anticoagulants versus antiplatelet therapy for preventing further vascular events after transient ischaemic attack or minor stroke of presumed arterial origin. Cochrane Database Syst Rev 2001; (4): CD001342Google Scholar
  77. 77.
    Shepherd J, Cobbe SM, Ford I, et al. The West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301–7PubMedCrossRefGoogle Scholar
  78. 78.
    Downs JR, Clearfield M, Weis S, et al. The AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998; 279: 1615–22PubMedCrossRefGoogle Scholar
  79. 79.
    The MASS Investigators. Effect of simvastatin on coronary atheroma, the Multicentre Anti-Atheroma Study (MAAS). Lancet 1994; 344: 633–8CrossRefGoogle Scholar
  80. 80.
    Goldstein GL, Brown MS. Regulation of the mevalonate pathway. Nature 1990; 343: 425–30PubMedCrossRefGoogle Scholar
  81. 81.
    Colli S, Eligini S, Lalli M, et al. Vastatins inhibit tissue factor in cultured human macrophages: a novel mechanism of protection against atherosclerosis. Arterioscler Thromb Vasc Biol 1997; 17: 265–72PubMedCrossRefGoogle Scholar
  82. 82.
    Mayer L, Eller T, Brauer P, et al. Effect of long term treatment with lovastatin on the clotting system and blood platelets. Ann Hematol 1992; 64: 196–201PubMedCrossRefGoogle Scholar
  83. 83.
    Cairns JA, Theroux P, Lewis Jr HD, et al. Anti-thrombotic agents in coronary artery disease. Chest 2001; 119: S228–52CrossRefGoogle Scholar
  84. 84.
    Hurlen M, Abdelnoor M, Smith P, et al. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002; 347: 969–74PubMedCrossRefGoogle Scholar
  85. 85.
    Wallentin L, Wilcox RG, Weaver WD, et al. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet 2003; 362: 789–97PubMedCrossRefGoogle Scholar
  86. 86.
    The Norwegian Multicenter Study Group. Timolol induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981; 304: 801–7CrossRefGoogle Scholar
  87. 87.
    Shilpak MG, Browner WS, Noguchi H, et al. Comparison of the effects of angiotensin converting enzyme inhibitors and beta blockers on survival in elderly patients with reduced left ventricular function after myocardial infarction. Am J Med 2001; 110: 425–33CrossRefGoogle Scholar
  88. 88.
    Rochon PA, Tu JV, Anderson GM, et al. Rate of heart failure and 1-year survival for older people receiving low-dose beta-blocker therapy after myocardial infarction. Lancet 2000; 356: 639–44PubMedCrossRefGoogle Scholar
  89. 89.
    Wei L, Flynn R, Murray GD, et al. Use and adherence to beta-blockers for secondary prevention of myocardial infarction: who is not getting the treatment? Pharmacoepidemiol Drug Saf 2004; 13: 761–6PubMedCrossRefGoogle Scholar
  90. 90.
    Everly MJ, Heaton PC, Cluxton Jr RJ. Beta-blocker underuse in secondary prevention of myocardial infarction. Ann Pharmacother 2004; 38: 286–93PubMedGoogle Scholar
  91. 91.
    Yusuf S, Pepine CJ, Garces C, et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fraction. Lancet 1992; 340: 1173–8PubMedCrossRefGoogle Scholar
  92. 92.
    The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with evidence of heart failure. Lancet 1993; 342: 821–8Google Scholar
  93. 93.
    Stampfer MJ, Colditz GA, Willet WC, et al. Post menopausal estrogen therapy and cardiovascular disease: ten-year follow up from the Nurses’ Health Study. N Engl J Med 1991; 325: 756–62PubMedCrossRefGoogle Scholar
  94. 94.
    Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of ischemic heart disease in post menopausal women: Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280: 605–13PubMedCrossRefGoogle Scholar
  95. 95.
    Cherry N, Gilmour K, Hannoford P, et al. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet 2002; 360: 2001–8PubMedCrossRefGoogle Scholar
  96. 96.
    Stevenson JC, Oladipo A, Manassiev N, et al. Randomized trial of effect of transdermal continuous combined hormone replacement therapy on cardiovascular risk markers. Br J Haematol 2004; 124: 802–8PubMedCrossRefGoogle Scholar
  97. 97.
    Post MS, Christella M, Thomassen LG, et al. Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women. Arterioscler Thromb Vasc Biol 2003; 23: 1116–21PubMedCrossRefGoogle Scholar
  98. 98.
    Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 2003; 289: 2534–44PubMedCrossRefGoogle Scholar
  99. 99.
    Kostis JB, Davis BR, Cutler J, et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA 1997; 278: 212–6PubMedCrossRefGoogle Scholar
  100. 100.
    ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981–97CrossRefGoogle Scholar
  101. 101.
    Arnold JM, Yusuf S, Young J, et al. Prevention of heart failure in patients in the Heart Outcomes Prevention Evaluation (HOPE) study. Circulation 2003; 107: 1284–90PubMedCrossRefGoogle Scholar
  102. 102.
    Nichol KL, Nordin J, Mullooly J, et al. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N Engl J Med 2003; 348: 1322–32PubMedCrossRefGoogle Scholar
  103. 103.
    LaCroix AZ, Lang J, Scherr P, et al. Smoking and mortality among older men and women in three communities. N Engl J Med 1991; 324: 1619–25PubMedCrossRefGoogle Scholar
  104. 104.
    Ho SC, Zhan SY, Tang JL, et al. Smoking and mortality in an older Chinese cohort. J Am Geriatr Soc 1999; 47: 1445–50PubMedGoogle Scholar
  105. 105.
    Tessier JF, Nejjari C, Letenneur L, et al. Smoking and eight-year mortality in an elderly cohort. Int J Tuberc Lung Dis 2000; 4: 698–704PubMedGoogle Scholar
  106. 106.
    Dale LC, Olsen DA, Patten CA, et al. Predictors of smoking cessation among elderly smokers treated for nicotine dependence. Tob Control 1997; 6: 181–7PubMedCrossRefGoogle Scholar
  107. 107.
    Orleans CT, Resch N, Noll E, et al. Use of transdermal nicotine in a state-level prescription plan for the elderly: a first look at ‘real-world’ patch users. JAMA 1994; 271: 601–7PubMedCrossRefGoogle Scholar
  108. 108.
    Daughton D, Susman J, Sitorius M, et al. Transdermal nicotine therapy and primary care. Importance of counselling, demographic, and participant selection factors on 1-year quit rates: the Nebraska Primary Practice Smoking Cessation Trial Group. Arch Fam Med 1998; 7: 425–30PubMedCrossRefGoogle Scholar
  109. 109.
    Powell KE, Thompson PD, Caspersen CJ, et al. Physical activity and the incidence of coronary artery disease. Annu Rev Public Health 1987; 8: 253–87PubMedCrossRefGoogle Scholar
  110. 110.
    Paffenbarger RS, Hyde RT, Wing AL, et al. The association of changes in physical activity levels and other lifestyle characteristics with mortality among men. N Engl J Med 1993; 328: 538–45PubMedCrossRefGoogle Scholar
  111. 111.
    Rosengren A, Wilhelmsen L. Physical activity protects against coronary death and deaths from all causes in middle-aged men: evidence from a 20-year follow-up of the primary prevention study in Goteborg. Ann Epidemiol 1997; 7: 69–75PubMedCrossRefGoogle Scholar
  112. 112.
    Eaton CB, Medalie JH, Flocke SA, et al. Self-reported physical activity predicts long-term coronary heart disease and all-cause mortalities: twenty-one-year follow-up of the Israeli Ischemic Heart Disease Study. Arch Fam Med 1995; 4: 323–9PubMedCrossRefGoogle Scholar
  113. 113.
    Wannamethee SG, Gerald Shaper A, Walker M. Changes in physical activity, mortality, and incidence of coronary heart disease in older men. Lancet 1998; 351: 1603–8PubMedCrossRefGoogle Scholar
  114. 114.
    Gregg EW, Cauley JA, Stone K, et al. Relationship of changes in physical activity and mortality among older women. JAMA 2003; 289: 2379–86PubMedCrossRefGoogle Scholar
  115. 115.
    Schnohr P, Scharling H, Jensen JS. Changes in leisure-time physical activity and risk of death: an observational study of 7000 men and women. Am J Epidemiol 2003; 158: 639–44PubMedCrossRefGoogle Scholar
  116. 116.
    Lavie CJ, Milani RV. Benefits of cardiac rehabilitation and exercise training programs in elderly coronary patients. Am J Geriatr Cardiol 2001; 10: 323–7PubMedCrossRefGoogle Scholar
  117. 117.
    Hung C, Daub B, Black B, et al. Exercise training improves overall physical fitness and quality of life in older women with coronary artery disease. Chest 2004; 126: 1026–31PubMedCrossRefGoogle Scholar
  118. 118.
    Lavie CJ, Milani RV, Littman AB. Benefit of cardiac rehabilitation and exercise training in secondary coronary prevention in the elderly. J Am Coll Cardiol 1993; 22: 678–83PubMedCrossRefGoogle Scholar
  119. 119.
    Stampfer MJ, Hu FB, Manson JE, et al. Primary prevention of coronary heart disease in women through diet and lifestyle. N Engl J Med 2000; 343: 16–22PubMedCrossRefGoogle Scholar
  120. 120.
    Mozaffarian D, Longstreth Jr WT, Lemaitre RN, et al. Fish consumption and stroke risk in elderly individuals: the Cardiovascular Health Study. Arch Intern Med 2005; 165: 200–6PubMedCrossRefGoogle Scholar
  121. 121.
    Huijbregts P, Feskens E, Räsänen L, et al. Dietary pattern and 20-year mortality in elderly men in Finland, Italy, and the Netherlands: longitudinal cohort study. BMJ 1997; 315: 13–7PubMedCrossRefGoogle Scholar
  122. 122.
    Knoops KT, de Groot LC, Kromhout D, et al. Mediterranean diet, lifestyle factors, and 10-year mortality in elderly European men and women: the HALE project. JAMA 2004; 292: 1433–9PubMedCrossRefGoogle Scholar
  123. 123.
    Janszky I, Mukamal KJ, Orth-Gomer K, et al. Alcohol consumption and coronary atherosclerosis progression: the Stockholm Female Coronary Risk Angiographic Study. Atherosclerosis 2004; 176: 311–9PubMedCrossRefGoogle Scholar
  124. 124.
    Hooper L, Bartlett C, Davey SG, et al. Advice to reduce dietary salt for prevention of cardiovascular disease. Cochrane Database Syst Rev 2004; (1): CD003656Google Scholar
  125. 125.
    Hart RG. Warfarin in atrial fibrillation: underused in the elderly, often inappropriately used in the young. Heart 1999; 82: 539–40PubMedGoogle Scholar
  126. 126.
    Majumdar SR, Gurwitz JH, Soumerai SB. Undertreatment of hyperlipidemia in the secondary prevention of coronary artery disease. J Gen Intern Med 1999; 14: 711–7PubMedCrossRefGoogle Scholar
  127. 127.
    Hulley SB, Grady D, Browner WS. Statins: underused by those who would benefit: but caution is needed for young people at low risk of cardiovascular disease. BMJ 2000; 321: 971–2PubMedCrossRefGoogle Scholar
  128. 128.
    Everly MJ, Heaton PC, Cluxton Jr RJ. Beta-blocker underuse in secondary prevention of myocardial infarction. Ann Pharmacother 2004; 38: 286–93PubMedGoogle Scholar
  129. 129.
    Foody JM, Ferdinand FD, Galusha D, et al. Patterns of secondary prevention in older patients undergoing coronary artery bypass grafting during hospitalization for acute myocardial infarction. Circulation 2003; 108Suppl. 1: II24–8PubMedGoogle Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  • Wafik Farah Andrawes
    • 1
  • Caroline Bussy
    • 1
  • Joël Belmin
    • 1
  1. 1.Service de GériatrieHôpital Charles Foix et Université Paris 6Ivry-sur-SeineFrance

Personalised recommendations